{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:24:58Z","timestamp":1792211098136,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01245-5","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T12:53:51Z","timestamp":1743425631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score\u2013matched study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"Alex","family":"Bataller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Urrutia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bazinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-2264","authenticated-orcid":false,"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Bouligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-397X","authenticated-orcid":false,"given":"Mahesh","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-8248","authenticated-orcid":false,"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Oganesian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold N.","family":"Keer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"1245_CR1","doi-asserted-by":"crossref","unstructured":"Garcia-Manero, G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1307\u201325.","DOI":"10.1002\/ajh.26984"},{"key":"1245_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1182\/asheducation-2016.1.478","volume":"2016","author":"W Saber","year":"2016","unstructured":"Saber W, Horowitz MM. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematol Am Soc Hematol Educ Program. 2016;2016:478\u201384.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1245_CR3","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1245_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:1\u201314.","journal-title":"NEJM Evid"},{"key":"1245_CR5","first-page":"2047","volume":"141","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Ad\u00e8sAd L, Borate U, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141:2047\u201361.","journal-title":"Blood"},{"key":"1245_CR6","doi-asserted-by":"publisher","first-page":"106555","DOI":"10.1016\/j.leukres.2021.106555","volume":"104","author":"JS Garcia","year":"2021","unstructured":"Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ, et al. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021;104:106555.","journal-title":"Leuk Res"},{"key":"1245_CR7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/hematology.2022000351","volume":"2022","author":"KL Koenig","year":"2022","unstructured":"Koenig KL, Borate U. New investigational combinations for higher-risk MDS. Hematology. 2022;2022:368\u201374.","journal-title":"Hematology"},{"key":"1245_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/10428194.2024.2344061","volume":"65","author":"G Gener-Ricos","year":"2024","unstructured":"Gener-Ricos G, Rodriguez-Sevilla JJ, Urrutia S, Bataller A, Bazinet A, Garcia-Manero G. Advances in the management of higher-risk myelodysplastic syndromes: future prospects. Leuk Lymphoma. 2024;65:1233\u201344.","journal-title":"Leuk Lymphoma"},{"key":"1245_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, et al. Oral cedazuridine\/decitabine for MDS and CMML: A phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood. 2020;136:674\u201383.","journal-title":"Blood"},{"key":"1245_CR10","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et al. Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11:e15\u2013e26.","journal-title":"Lancet Haematol"},{"key":"1245_CR11","unstructured":"Otsuka. Inqovi (decidabine and cedazuridine) [package insert]. U.S. Food and Drug Administration. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212576s000lbl.pdf. Accessed October 2024."},{"key":"1245_CR12","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","volume":"7","author":"JD Leverson","year":"2017","unstructured":"Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 2017;7:1376\u201393.","journal-title":"Cancer Discov"},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/leu.2015.179","volume":"30","author":"S Jilg","year":"2015","unstructured":"Jilg S, Reidel V, M\u00fcller-Thomas C, K\u00f6nig J, Schauwecker J, H\u00f6ckendorf U, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2015;30:112\u201323.","journal-title":"Leukemia"},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","volume":"91","author":"T Tsao","year":"2012","unstructured":"Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012;91:1861\u201370.","journal-title":"Ann Hematol"},{"key":"1245_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"1245_CR16","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","volume":"9","author":"A Bazinet","year":"2022","unstructured":"Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study. Lancet Haematol. 2022;9:e756\u201365.","journal-title":"Lancet Haematol"},{"key":"1245_CR17","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1002\/ajh.26539","volume":"97","author":"N Gangat","year":"2022","unstructured":"Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM, et al. Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. Am J Hematol. 2022;97:E214\u201316.","journal-title":"Am J Hematol"},{"key":"1245_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1182\/blood-2020-139492","volume":"136","author":"JS Garcia","year":"2020","unstructured":"Garcia JS, Wei AH, Borate U, Fong CY, Baer MR, Nolte F, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Blood. 2020;136:55\u20137.","journal-title":"Blood"},{"key":"1245_CR19","doi-asserted-by":"publisher","first-page":"E433","DOI":"10.1002\/ajh.26334","volume":"96","author":"AN Saliba","year":"2021","unstructured":"Saliba AN, Litzow MR, Gangat N, Al-Kali A, Foran JM, Hogan WJ, et al. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. Am J Hematol. 2021;96:E433\u201336.","journal-title":"Am J Hematol"},{"key":"1245_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajh.26771","volume":"98","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98:272\u201381.","journal-title":"Am J Hematol"},{"key":"1245_CR21","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","volume":"4","author":"BJ Ball","year":"2020","unstructured":"Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4:2866\u201370.","journal-title":"Blood Adv"},{"key":"1245_CR22","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(23)00367-8","volume":"11","author":"A Bataller","year":"2024","unstructured":"Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, et al. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1\/2 study. Lancet Haematol. 2024;11:e186\u201395.","journal-title":"Lancet Haematol"},{"key":"1245_CR23","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1080\/10428194.2022.2084730","volume":"63","author":"R Khanam","year":"2022","unstructured":"Khanam R, Shahzad M, Chaudhary SG, Ali F, Shah Z, Pachika PS, et al. Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. Leuk Lymphoma. 2022;63:2671\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1245_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3324\/haematol.2013.093765","volume":"99","author":"R Luthra","year":"2014","unstructured":"Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99:465\u201373.","journal-title":"Haematologica"},{"key":"1245_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"1245_CR26","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2352-3026(22)00265-4","volume":"10","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G. Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. Lancet Haematol. 2023;10:e71\u20138.","journal-title":"Lancet Haematol"},{"key":"1245_CR27","doi-asserted-by":"publisher","first-page":"TPS7054","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7054","volume":"39","author":"AM Zeidan","year":"2021","unstructured":"Zeidan AM, Garcia JS, Fenaux P, Platzbecker U, Miyazaki Y, Xiao Z-J, et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes. J Clin Oncol. 2021;39:TPS7054.","journal-title":"J Clin Oncol"},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00541-0","volume":"11","author":"NE Rahmani","year":"2021","unstructured":"Rahmani NE, Ramachandra N, Sahu S, Gitego N, Lopez A, Pradhan K, et al. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer J. 2021;11:1\u20138.","journal-title":"Blood Cancer J"},{"key":"1245_CR29","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1158\/1078-0432.CCR-23-2860","volume":"30","author":"A Bazinet","year":"2024","unstructured":"Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, et al. Cytogenetic and molecular associations with outcomes in higher-risk myelodysplastic syndromes treated with hypomethylating agents plus venetoclax. Clin Cancer Res. 2024;30:1319\u201326.","journal-title":"Clin Cancer Res"},{"key":"1245_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","volume":"104","author":"CS Cutler","year":"2004","unstructured":"Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pe\u0301rez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579\u201385.","journal-title":"Blood"},{"key":"1245_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41375-024-02466-6","volume":"39","author":"D Tremblay","year":"2025","unstructured":"Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, et al. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2025;39:257\u201360.","journal-title":"Leukemia"},{"key":"1245_CR32","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01245-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:51:35Z","timestamp":1762278695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01245-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01245-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KS reports fees for professional activities from Amgen, Chugai Pharmaceutical, Daiichi Sankyo Company, Novartis, Otsuka Pharmaceutical Co., Ltd, and Pfizer. Kelly Chien declares honoraria from Otsuka Pharma, and consultancy fee from Pfizer Japan. GCI reports consulting or advisory role for Novartis, Kura Oncology, Syndax, NuProbe, AbbVie, and Sanofi, and research funding from Novartis, Syndax, Kura Oncology, Merck, Cullinan Oncology, Astex Pharmaceuticals and NuProbe. NJS has been a consultant for Takeda Oncology, AstraZeneca, Amgen, Novartis, and Pfizer and received research funding from Takeda Oncology, Astellas, and Stemline Therapeutics as well as honoraria from Amgen. CDDi has been a board of directors or advisory committee member for Genmab, GSK, Kura Oncology, and Notable Labs; has received honoraria from Kura, Astellas Pharma, Bluebird Bio, Bristol-Myers Squibb, Foghorn Therapeutics, Immune-Onc Therapeutics, Novartis, Takeda Oncology, Gilead Sciences, and Jazz Pharmaceuticals; is a current holder of stock options for Notable Labs; has been a consultant for AbbVie and Servier; and has received research funding from Servier, Bristol-Myers Squibb, Foghorn, Immune-Onc Therapeutics, Loxo Oncology, Astex Pharmaceuticals, Cleave, and Forma. TMK has been a consultant for AbbVie, Agios, BMS, Genentech, Jazz Pharmaceuticals, Novartis, Servier, and PinotBio; has received research funding from AbbVie, BMS, Genentech, Jazz Pharmaceuticals, Pfizer, Cellenkos, Ascentage Pharma, GenFleet Therapeutics, Astellas Pharma, AstraZeneca, Amgen, Cyclacel Pharmaceuticals, Delta-Fly Pharma, Iterion Therapeutics, GlycoMimetics, and Regeneron Pharmaceuticals; and has received honoraria from Astex Pharmaceuticals. EJ has been a consultant for AbbVie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Novartis, Pfizer Canada Inc., and Takeda Oncology. FR has received research funding from Amgen, Astex Pharmaceuticals\/Taiho Oncology, BMS\/Celgene, Syos, AbbVie, Prelude, Xencor, Astellas Pharma, and Biomea Fusion as well as honoraria from Amgen, BMS\/Celgene, Syos, AbbVie, and Astellas Pharma; has been a board of directors or advisory committee member for Astex Pharmaceuticals\/Taiho Oncology; and has been a consultant for BMS\/Celgene, Syos, Novartis, AbbVie, AstraZeneca, and Astellas Pharma. GJR is a consultant for Agios, Amgen, Amphivena, Astex, Celator, Celgene, Clovis Oncology, CTI BioPharma, Genoptix, Immune Pharmaceuticals, Janssen Pharmaceuticals, Juno, MedImmune, MEI Pharma, Onconova, Pfizer, Roche, and Sunesis; receives research funding from AbbVie, BMS, Teva, and Karyopharm; is an advisory board member or consultant for Novartis, AbbVie, BeiGene, BerGenBio, Arcellx, Jazz Pharmaceuticals, Syros, BMS, Genentech, ImmunoGen, AstraZeneca, Kura, Ryvu, Magenta, and Qihan Zentalis; and has provided research support to Janssen. MRS declares research funding to institution from ALX Oncology, Astex, Incyte, Takeda, and TG Therapeutics; consultancy fees from AbbVie, Bristol Myers Squibb, CTI BioPharma, Forma, Geron, GlaxoSmithKline, Karyopharm, Rigel, Ryvu, Taiho, and Treadwell; stock or stock options in Empath Bioscience, Karyopharm, and Ryvu; and medical writing support for this work from Kura Oncology. EAG declares Honoraria from AAMDS, MedscapeLive, MediCom Worldwide, MJH Health, ASH, MDS International Foundation, Physicians Educational Resource. Consulting from Abbvie, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Takeda Oncology, Astex Pharmaceuticals\/Taiho Oncology, Alexion\/AstraZeneca Rare disease, Celgene\/Bristol-Myers Squibb, CTI Biopharma, Novartis, Partner Therapeutics, Picnic Health, Servier. Research Funding: Alexion Pharmaceuticals, Apellis, Astex\/Otsuka Pharmaceuticals\/Taiho Oncology, Blueprint Medicines, Celldex Pharmaceuticals, Genentech Inc, NextCure, Inc. JMcC reported receipt of personal fees from BMS, Takeda, Blueprint Medicine, PharmaEssentia, CTI, GSK, Incyte, Amgen, and Jazz Pharmaceuticals. OO reports consulting fees from AbbVie, Blueprint Medicines, Bristol Myers Squibb, CTI, Impact Biomedicines, Kymera, Novartis, SERVIER, Taiho Pharmaceutical, and Treadwell Therapeutics; and received research funding (to institution) from AbbVie, Agios, Aprea AB, Astex Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Celgene, CTI BioPharma Corp, Daiichi Sankyo, Incyte, Janssen Oncology, Kartos Therapeutics, Loxo, Novartis, NS Pharma, and OncoTherapy Science. AO, HK, and MA are\/were employed by Astex\/Taiho Oncology. HMK has received research funding from AbbVie, Amgen, Ascentage Pharma, BMS, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, and Novartis as well as honoraria from AbbVie, Amgen, Amphista Therapeutics, Ascentage Pharma, Astellas Pharma, Biologix, Curis, Ipsen, KAHR, Novartis, Pfizer, Precision Biosciences, Shenzhen TargetRx, and Takeda Oncology. Guillermo Garcia-Manero declares support from and an advisory role with Celgene Corporation, Astex, and Amphivena, and grant\/research support 15 from Helsinn, Novartis, AbbVie, Onconova, H3 Biomedicine, and Merck. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}